Development of 177Lu-DOTA-anti-CD20 for radioimmunotherapy

Synthesis and Preclinical Evaluation of177Lu-CHX-A”-DTPA-Rituximab as a Radioimmunotherapeutic Agent for Non-Hodgkin's Lymphoma

“…18 There are many literature reports on the preparation and preclinical evaluation of 177 Lu-DOTARituximab as a radioimmunotherapy agent for NHL. [40][41][42] Earlier, Michel et al had reported the preparation and evaluation of 177 Lu-labeled anti-CD20 for therapy using benzyl DTPA as the chelator. 43 However, data with respect to the equilibrium dissociation constant (K d ) and tumor uptake of 177 Lu-labeled anti-CD20 are not available in the literature, to the best of their knowledge.…”

Production, quality control, biodistribution assessment and preliminary dose evaluation of [177Lu]-tetra phenyl porphyrin complex as a possible therapeutic agent

“…Production and quality control of 177 LuCl 3 solution 177 Lu was produced by irradiation of natural Lu 2 O 3 target (1 mg) at a thermal neutron flux of approximately 4 × 10 13 n/cm 2 .s for 5 days at Tehran Research Reactor (TRR) according to the reported procedures (Yousefnia et al, 2011). The irradiated target was dissolved in 200 µL of 1.0 M HCl, to prepare 177 LuCl 3 and diluted to the appropriate volume with ultra pure water, to produce a stock solution of final volume of 5 mL with approximately 2.8 GBq.…”

Preclinical evaluation of holmium‐166 labeled anti‐VEGF‐A(Bevacizumab)

“…Thus, there was no evidence for either degradation or transchelation of 166 Ho to other serum proteins over a period consistent with the normal blood clearance time of bevacizumab. Similar to other DOTA‐radiolabeled immunoconjugates such as Lu‐DOTA‐rituximab, the radiolabeled compound possessed significant stability in the final formulation and also in the presence of human serum in vitro …”